ORASURE TECHNOLOGIES Business Summary

OraSure Technologies Inc. (OSUR) operates a dual-segment business model focused on the development and distribution of point-of-care diagnostic tests and molecular sample management solutions. The company generates revenue primarily through the sale of proprietary oral fluid-based diagnostic devices for infectious diseases (HIV, HCV, and Ebola) and substance abuse, alongside its Sample Management Solutions segment, which provides kits for the collection and stabilization of genetic material for genomics and proteomics research. Following a significant post-pandemic decline in COVID-19 testing demand, OraSure is pivoting toward high-growth molecular diagnostics, bolstered by the 2024 acquisition of Sherlock Biosciences and its CRISPR-based platform. The company competes directly with global diagnostics giants such as Abbott Laboratories, Roche, and QuidelOrtho, as well as specialized players like Chembio Diagnostics. Within this landscape, OraSure maintains a dominant niche in non-invasive oral fluid testing and is currently undergoing a strategic transformation to capture the emerging at-home STI and sickle cell testing markets. Originally formed through the 2000 merger of Epitope and STC Technologies, the company was founded by a team including Mike Gausling, Sam Niedbala, and William Spencer. Today, the leadership is spearheaded by President and CEO Carrie Eglinton Manner, who joined in 2022 following senior executive roles at Quest Diagnostics and GE Healthcare. The executive team includes CFO Kenneth J. McGrath and Rafal Iwasiow, Ph.D., who serves as the lead for Science, Innovation, and Technology. The company’s governance has seen recent significant refreshment, with John P. Kenny serving as Board Chair and the 2025 appointment of healthcare investor Steven K. Boyd to the board. OraSure is currently a target of activist interest from Altai Capital, led by Rishi Bajaj, which holds a 5.2% stake and has nominated candidates for the 2026 board elections to influence capital allocation and strategic direction.